KM-819 (or KR-33493), which is under development by Kainos Medicine, Inc. (Seongnam, Korea), is a pioneering FAF1 inhibitor and candidate for PD and MSA treatment and has been demonstrated to show potential for inhibiting dopaminergic neuronal cell death and activating α-syn degradation via autophagy. This evidence concerns the gene FAF1 and Parkinson disease.